NCT03704675 is a Phase 1 clinical trial of TEW-7197 in Healthy Volunteers, sponsored by MedPacto, Inc..

Who is sponsoring NCT03704675?

NCT03704675 is sponsored by MedPacto, Inc..

What drugs are being tested in NCT03704675?

Interventions in NCT03704675: TEW-7197.

What condition does NCT03704675 study?

NCT03704675 studies Healthy Volunteers.

Is NCT03704675 still recruiting?

NCT03704675 is currently completed. Last updated 14 April 2020.

Last reviewed 2020-04-14 · How we verify

NCT03704675

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effect of Food on the Pharmacokinetics of TEW-7197 in Healthy Subjects

Completed Phase 1 Last updated 14 April 2020

What this trial tests

Phase 1 trial testing TEW-7197 in Healthy Volunteers in 16 participants. Completed in 20 October 2018.

Timeline

8 August 2018

Primary endpoint
9 September 2018

20 October 2018

Quick facts

Lead sponsor	MedPacto, Inc.
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	none
Primary purpose	basic science
Enrollment	16
Start date	8 August 2018
Primary completion	9 September 2018
Estimated completion	20 October 2018
Sites	1 location across South Korea

Drugs / interventions tested

TEW-7197 — full drug profile →

Conditions studied

Healthy Volunteers — all drugs for Healthy Volunteers →

Sponsor

MedPacto, Inc. — full company profile →

Who can join

Adults 19 to 45, male only, with Healthy Volunteers. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Participants in this study will receive 200 milligram (mg) TEW-7197 taken at 7days apart. One dose will be given under fasting . The Other dose will be given with a high fat meal. The study will evaluate the effect of a high fat meal on how much of the drug gets into the blood stream. Side effects will be documented. This study will last approximately 2weeks not including screening.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

The molecular mechanisms and therapeutic strategies of EMT in tumor progression and metastasis.
Huang Y, Hong W, Wei X. · · 2022 · cited 719× · PMID 36076302 · DOI 10.1186/s13045-022-01347-8

Verify or expand the search:

Other trials of TEW-7197

Trials testing the same drug.

NCT03732274 — Phase 1b/2a, Open-label Study of Vactosertib in Combination With Durvalumab in Advanced NSCLC · Phase 1, PHASE2 · completed
NCT03724851 — Vactosertib in Combination with Pembrolizumab in Metastatic Colorectal or Gastric Cancer · Phase 1, PHASE2 · completed
NCT03698825 — TEW-7197 with Paclitaxel for the Treatment of Metastatic Gastric Cancer · Phase 1, PHASE2 · completed
NCT03074006 — Dose Escalation and Proof-of-Concept Studies of Vactosertib (TEW-7197) Monotherapy in Patients With MDS · Phase 1 · completed
NCT02160106 — First in Human Dose Escalation Study of Vactosertib (TEW-7197) in Subjects With Advanced Stage Solid Tumors · Phase 1 · completed

Other recruiting trials for Healthy Volunteers

Currently open trials in the same condition.

NCT07504003 — Influence of Training Session Duration on Improvements in Physiological Resilience to Exercise · NA · recruiting
NCT07446400 — A Trial to Examine the Interaction of Repinatrabit With Ethinyl Estradiol/Norethindrone, Metformin,Carbamazepine, Rosuva · Phase 1 · recruiting
NCT07495813 — A Study to See How RO7763505 Works and How Safe it is When Given to Healthy People and People With Stable Heart Disease · Phase 1 · recruiting
NCT07499050 — A Study of Multiple Doses of Orally Administered RO7795081 in Otherwise Healthy Chinese Adult Participants With Obesity · Phase 1 · recruiting
NCT07342114 — A Dose-Escalation Study of RO7875913 in Healthy Participants · Phase 1 · recruiting

Other MedPacto, Inc. trials

Trials by the same sponsor.

NCT06219733 — Vactosertib and Imatinib Combination in Patients with Advanced Desmoid Tumor/aggressive Fibromatosis (DT/AF) · Phase 2 · withdrawn
NCT04515979 — Vactosertib in Combination with Pembrolizumab for PD-L1 Positive Non-small Cell Lung Cancer (NSCLC) Subjects · Phase 2 · terminated
NCT04064190 — Vactosertib with Durvalumab in Urothelial Carcinoma Failing Checkpoint Inhibition · Phase 2 · withdrawn
NCT03732274 — Phase 1b/2a, Open-label Study of Vactosertib in Combination With Durvalumab in Advanced NSCLC · Phase 1, PHASE2 · completed
NCT03724851 — Vactosertib in Combination with Pembrolizumab in Metastatic Colorectal or Gastric Cancer · Phase 1, PHASE2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03704675 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by MedPacto, Inc.
Last refreshed: 14 April 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03704675.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing